Compare TRMB & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRMB | EXAS |
|---|---|---|
| Founded | 1978 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 19.3B |
| IPO Year | 1990 | N/A |
| Metric | TRMB | EXAS |
|---|---|---|
| Price | $79.59 | $101.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 20 |
| Target Price | ★ $96.43 | $80.25 |
| AVG Volume (30 Days) | 1.3M | ★ 3.0M |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $3,600,900,000.00 | $3,082,033,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $7.45 | $13.51 |
| P/E Ratio | $54.71 | ★ N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $52.91 | $38.81 |
| 52 Week High | $87.50 | $102.66 |
| Indicator | TRMB | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 82.28 |
| Support Level | $76.72 | $101.51 |
| Resistance Level | $81.95 | $101.89 |
| Average True Range (ATR) | 1.49 | 0.35 |
| MACD | -0.08 | -1.01 |
| Stochastic Oscillator | 49.42 | 63.64 |
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.